{
  "docId": "019de075-e341-775b-a82c-decdaeb5c03e",
  "docSlug": "c5ed60c4cc85a094dbae2fa13cb26a34",
  "documentTitle": "Alkermes | Investor Presentation Deck | 37 slides",
  "authorId": "alkermes",
  "authorName": "Mural Oncology",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 37,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "other",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide outlines a clinical trial protocol with three distinct cohorts and specific dosing schedules.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/22",
  "deckHref": "/decks/019de075-e341-775b-a82c-decdaeb5c03e",
  "deckJsonHref": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json",
  "deckAnchorHref": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.35,
        "x": 0.32,
        "y": 0.3
      },
      "kind": "diagram",
      "text": "Cohort dosing diagrams for Cohorts 1, 2, and 3 showing treatment cycles and dosing frequency",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "65fa974a-6b0f-45e8-a701-dcee4d7fb552",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.28,
        "x": 0.05,
        "y": 0.34
      },
      "kind": "list",
      "text": "Key eligibility criteria: Unresectable/metastatic melanoma, prior anti-PD(L)-1, max 1 prior therapy, measurable disease, ECOG PS 0-1",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2c671a53-46e4-4112-93e7-ee9f57941aa0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.28,
        "x": 0.68,
        "y": 0.35
      },
      "kind": "list",
      "text": "Key endpoints: Primary (ORR per RECIST v1.1), Key secondary (DOR, PFS, DCR, TTR)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "82e24340-9273-4c1a-bf2b-33cd25288413",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "Footnotes regarding clinical trial registration, references, and dosing cycle exceptions.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1eb6019e-de06-47bb-be04-80c482fdfec0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.06,
        "y": 0.06
      },
      "kind": "title",
      "text": "ARTISTRY-6: Phase 2 / Potentially Registrational Study for Mucosal Melanoma",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0730469-7416-4b26-afe3-0188578bf6f9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}